GFAP and Alzheimer disease: The addition of SOST to the models including the BM plus known AD-related biomarkers (p-tau181, p-tau231, GFAP and Aβ42/Aβ40 ratio) also reached a higher discriminative accuracy between individuals with Aβ+ status from those with Aβ− status, while not to a significant level, neither (AUC = 0.806 vs 0.836, P = 0.27 for BM + p-tau181 vs BM + p-tau181 + SOST; AUC = 0.838 vs 0.852, P = 0.47 for BM + p-tau231 vs BM + p-tau231 + SOST; AUC = 0.916 vs 0.918, P = 0.69 for BM + GFAP vs BM + GFAP + SOST; AUC = 0.833 vs 0.857, P = 0.27 for BM + Aβ42/Aβ40 vs BM + Aβ42/Aβ40 + SOST; Fig. 2c–e).